Axillary Lymph Node Micrometastases Decrease Triple-negative Early Breast Cancer Survival

Overview

Journal Br J Cancer

Specialty Oncology

Date 2016 Sep 30

PMID 27685443

Citations 13

Authors

G Houvenaeghel

R Sabatier

F Reyal

J M Classe

S Giard

H Charitansky

R Rouzier

C Faure

J R Garbay

E Darai

D Hudry

P Gimbergues

R Villet

E Lambaudie

Affiliations

Soon will be listed here.

Abstract

Background: Triple-negative breast cancers (TNBCs) are the most deadly form of breast cancer (BC) subtypes. Axillary lymph node involvement (ALNI) has been described to be prognostic in BC taken as a whole, but its prognostic value in each subtype is unclear. We explored the prognostic impact of ALNI and especially of small size axillary metastases in early TNBCs.

Methods: We analysed in this multicentre study all patients treated for early TNBC in 12 French cancer centres. We explored the correlation between clinicopathological data and ALNI, with a specific focus on the dichotomisation between macrometastases and occult metastases, which is defined as the presence of isolated tumour cells or micrometastases. The prognostic value of ALNI both in terms of disease-free survival (DFS) and overall survival (OS) was also explored.

Results: We included 1237 TNBC patients. Five-year DFS and OS were 83.7% and 88.5%, respectively. The identified independent prognostic features for DFS were tumour size >20 mm (hazard ratio (HR)=1.86; 95% CI: 1.11-3.10, P=0.018), lymphovascular invasion (HR=1.69; 95% CI: 1.21-2.34, P=0.002) and ALNI both in case of macrometastases (HR=1.97; 95% CI: 1.38-2.81, P<0.0001) and occult metastases (HR=1.72; 95% CI: 1.1-2.71, P=0.019). DFS and OS were similar between tumours with occult metastases and macrometastases. Tumours presenting at least two pejorative features (out of ALNI, lymphovascular invasion and large tumour size) displayed a significantly poorer DFS in both the training set and validation set, independently of chemotherapy administration. Tumours with no more than one of the above-cited pejorative features had a 5-year OS of ⩾90% vs 70% for other cases (P<0.0001).

Conclusions: Axillary lymph node involvement is a key prognostic feature for early TNBC when isolated tumour cells were identified in lymph nodes. This impact is independent of chemotherapy use.

Citing Articles

Establishment and clinical application of a prognostic index for inflammatory status in triple-negative breast cancer patients undergoing neoadjuvant therapy using machine learning.

Sun H, Liang J, Xue S, Zhang X, Ding M, Zhu J BMC Cancer. 2024; 24(1):1559.

PMID: 39707255 PMC: 11660978. DOI: 10.1186/s12885-024-13354-8.

Alteration of DNA methyltransferases by eribulin elicits broad DNA methylation changes with potential therapeutic implications for triple-negative breast cancer.

Bagheri M, Lee M, Muller K, Miller T, Pattabiraman D, Christensen B Epigenomics. 2024; 16(5):293-308.

PMID: 38356412 PMC: 10910603. DOI: 10.2217/epi-2023-0339.

Negative Survival Impact of Occult Lymph Node Involvement in Small HER2-Positive Early Breast Cancer Treated by Up-Front Surgery.

Houvenaeghel G, Cohen M, Martino M, Reyal F, Classe J, Chauvet M Cancers (Basel). 2023; 15(18).

PMID: 37760536 PMC: 10526175. DOI: 10.3390/cancers15184567.

Transcriptome Meta-Analysis of Triple-Negative Breast Cancer Response to Neoadjuvant Chemotherapy.

Zhang W, Li E, Wang L, Lehmann B, Chen X Cancers (Basel). 2023; 15(8).

PMID: 37190123 PMC: 10137141. DOI: 10.3390/cancers15082194.

Neoadjuvant Chemotherapy for Breast Cancer: Evolution of Clinical Practice in a French Cancer Center Over 16 Years and Pathologic Response Rates According to Tumor Subtypes and Clinical Tumor Size: Retrospective Cohort Study.

Houvenaeghel G, de Nonneville A, Cohen M, Viret F, Rua S, Sabiani L J Surg Res (Houst). 2023; 5(3):511-525.

PMID: 36714356 PMC: 9879000. DOI: 10.26502/jsr.10020251.

References

Hansen N, Grube B, Ye X, Turner R, Brenner R, Sim M . Impact of micrometastases in the sentinel node of patients with invasive breast cancer. J Clin Oncol. 2009; 27(28):4679-84. DOI: 10.1200/JCO.2008.19.0686. View

Jacquin J, Jones S, Magne N, Chapelle C, Ellis P, Janni W . Docetaxel-containing adjuvant chemotherapy in patients with early stage breast cancer. Consistency of effect independent of nodal and biomarker status: a meta-analysis of 14 randomized clinical trials. Breast Cancer Res Treat. 2012; 134(3):903-13. DOI: 10.1007/s10549-011-1933-0. View

Vandenbroucke J, von Elm E, Altman D, Gotzsche P, Mulrow C, Pocock S . Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007; 4(10):e297. PMC: 2020496. DOI: 10.1371/journal.pmed.0040297. View

Parmigiani G, Berry D, Winer E, Tebaldi C, Iglehart J, Prosnitz L . Is axillary lymph node dissection indicated for early-stage breast cancer? A decision analysis. J Clin Oncol. 1999; 17(5):1465-73. DOI: 10.1200/JCO.1999.17.5.1465. View

Weaver D, Ashikaga T, Krag D, Skelly J, Anderson S, Harlow S . Effect of occult metastases on survival in node-negative breast cancer. N Engl J Med. 2011; 364(5):412-21. PMC: 3044504. DOI: 10.1056/NEJMoa1008108. View

von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M . Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014; 15(7):747-56. DOI: 10.1016/S1470-2045(14)70160-3. View

Sabatier R, Jacquemier J, Bertucci F, Esterni B, Finetti P, Azario F . Peritumoural vascular invasion: a major determinant of triple-negative breast cancer outcome. Eur J Cancer. 2011; 47(10):1537-45. DOI: 10.1016/j.ejca.2011.02.002. View

Foulkes W, Smith I, Reis-Filho J . Triple-negative breast cancer. N Engl J Med. 2010; 363(20):1938-48. DOI: 10.1056/NEJMra1001389. View

Galimberti V, Cole B, Zurrida S, Viale G, Luini A, Veronesi P . Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol. 2013; 14(4):297-305. PMC: 3935346. DOI: 10.1016/S1470-2045(13)70035-4. View

10.

Penault-Llorca F, Vincent-Salomon A, MacGrogan G, Roger P, Treilleux I, Valent A . [2014 update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France]. Ann Pathol. 2014; 34(5):352-65. DOI: 10.1016/j.annpat.2014.08.018. View

11.

Houvenaeghel G, Classe J, Garbay J, Giard S, Cohen M, Faure C . Prognostic value of isolated tumor cells and micrometastases of lymph nodes in early-stage breast cancer: a French sentinel node multicenter cohort study. Breast. 2014; 23(5):561-6. DOI: 10.1016/j.breast.2014.04.004. View

12.

Perou C, Sorlie T, Eisen M, van de Rijn M, Jeffrey S, Rees C . Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-52. DOI: 10.1038/35021093. View

13.

Maaskant-Braat A, van de Poll-Franse L, Voogd A, Coebergh J, Roumen R, Nolthenius-Puylaert M . Sentinel node micrometastases in breast cancer do not affect prognosis: a population-based study. Breast Cancer Res Treat. 2010; 127(1):195-203. DOI: 10.1007/s10549-010-1086-6. View

14.

Fisher B, Bauer M, Wickerham D, Redmond C, Fisher E, CRUZ A . Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer. 1983; 52(9):1551-7. DOI: 10.1002/1097-0142(19831101)52:9<1551::aid-cncr2820520902>3.0.co;2-3. View

15.

Chia S, Speers C, Bryce C, Hayes M, Olivotto I . Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies. J Clin Oncol. 2004; 22(9):1630-7. DOI: 10.1200/JCO.2004.09.070. View

16.

Dawson S, Provenzano E, Caldas C . Triple negative breast cancers: clinical and prognostic implications. Eur J Cancer. 2009; 45 Suppl 1:27-40. DOI: 10.1016/S0959-8049(09)70013-9. View

17.

Park S, Koo J, Kim M, Park H, Lee J, Lee J . Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. Breast. 2011; 21(1):50-7. DOI: 10.1016/j.breast.2011.07.008. View

18.

Liedtke C, Mazouni C, Hess K, Andre F, Tordai A, Mejia J . Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008; 26(8):1275-81. DOI: 10.1200/JCO.2007.14.4147. View

19.

Layeequr Rahman R, Crawford S, Siwawa P . Management of axilla in breast cancer - The saga continues. Breast. 2015; 24(4):343-53. DOI: 10.1016/j.breast.2015.03.010. View

20.

Bettelheim R, Penman H, Neville A . Prognostic significance of peritumoral vascular invasion in breast cancer. Br J Cancer. 1984; 50(6):771-7. PMC: 1977004. DOI: 10.1038/bjc.1984.255. View